AB-BIOTICS invites visitors to CPHI 2025 to stand 3.0A68 for an exclusive look at its latest advanced biotic solutions for specific health indications across the lifespan.
Attendees can explore innovative product line debuts, cutting-edge clinical data and new science-backed probiotic strains that empower pharma brands to deliver unique, tailored solutions with real impact.
AB-BIOTICS will introduce its Pediacare line of biotic solutions targeting a range of health indications from infancy to adolescence.
The portfolio features precision strains and blends that support gut health, skin health, immunity and cognition — backed by age-specific trials.
Visitors can also learn about ongoing and soon-to-be published trials set to further strengthen the offering.
AB-BIOTICS will also unveil its newest therapeutic area — healthy ageing.
The portfolio will include two products with freshly published clinical data, including its INNERIM blend, which was seen to reduce constipation in adults aged over 50 years old and has the potential to support mental wellbeing.
The portfolio will also include Latilactobacillus sakei LB-P12, a probiotic with pre-clinical and clinical evidence showing it supports joint pain and osteoarthritis.
The company has also expanded its Gyntima product line for women’s health and will showcase a new product, Gyntima Iron, which has published evidence on addressing iron deficiency due to menstruation.
AB-BIOTICS will also be spotlighting Gyntima Balance, consisting of the strain Lactobacillus gasseri KABP-064.
A recent study revealed that it colonises the vaginal microbiota of healthy women after oral administration, with the potential to promote vaginal health.
The team will be showcasing innovative solutions, including Gyntima Restore for vaginal health, AB-Protears to address dry eyes, allergies and ocular inflammation and LipiGO to support weight management.